somewordstoolate/Q2CRBench-3 huggingface dataset:
Reference: Tarp S, Furst DE, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. [Review]. Rheumatology. 2017;56(3):417.
Study design: SYSTEMATIC_REVIEW
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Singh JA WG, Christensen R, Tanjong Ghogomu E, Maxwell LJ, MacDonald JK, Filippini G, Skoetz N, Francis DK, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Cameron C, Lunn MPT, Tugwell P, Buchbinder R. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Library. 2016(4).
Study design: SYSTEMATIC_REVIEW
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: BLOMley MJ. Effectiveness of a Third Tumor Necrosis Factor-a-blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in Rheumatoid Arthritis. The Journal of Rheumatology. 2017;38(11):2355-61.
Study design: Observational Study
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: de Jong PHP, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Annals of the Rheumatic Diseases. 2013;72(1):72.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Moreland LW, Zhang J. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trial. Arthritis and Rheumatism. 2012;64(9):2824.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Haagsma C. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Weinblatt ME. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis & Rheumatology. 2017;69(10):1937.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, et al. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. Journal of Rheumatology. 2016;43(7):1268.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FH, Kievit W, van Vollenhoven RF, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: Open label, randomised controlled, non-inferiority trial. BMJ (Online). 2015;350(no pagination).
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Sanmarti R. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. Arthritis & Rheumatism. 2019;71(10):1616-25.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Fautrel B, Pham T, Alfaiate T, Gandjbakhch F, Foltz V, Morel J, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: Results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases. 2016;75(1):59.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Pablos JL. Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study. Clinical & Experimental Rheumatology. 2019;37:437-44.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Genovese MC, Bathon JM, Martin RW, Fleischmann RM, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis & Rheumatism. 2002;46(6):1443.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven Rv, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis & Rheumatism. 2006;54(1):26.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. American Journal of Managed Care. 2002;8(3):231.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: VIBEKE STRAND AMR, MARY A. CIFALDI, NAIJUN CHEN, SANJOY ROY, and DENNIS REVICKI. Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study. The Journal of Rheumatology. 2012;39(1):63-72.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: de La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers. [Review]. Joint, Bone, Spine: Revue du Rhumatisme. 2017;84(2):133.
Study design: SYSTEMATIC_REVIEW
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Emery P. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases. 2015;74(1):19.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.
Study design: SYSTEMATIC_REVIEW
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Ibrahim F, Lorente-Canovas B, Dore CJ, Bosworth A, Ma MH, Galloway JB, et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders? Rheumatology. 2017;56(11):2004.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Emery P. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Annals of the Rheumatic Diseases. 2017;76(1):96.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Detert J. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Annals of the Rheumatic Diseases. 2013;72(6):844.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Annals of the Rheumatic Diseases. 2014;73(6):1027.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Campbell LC, C.; Bhagat, S. S.; Parker, R. A.; Ostor, A. J. K. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford academic). 2010;50(3):552-62.
Study design: SYSTEMATIC_REVIEW
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Atsumi Tea. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis BMJ. 2016;75:75-83.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Kavanaugh A. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Annals of the Rheumatic Diseases. 2013;72(1):64.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Emery P. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis and Rheumatism. 2009;60(8):2272.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Emery P. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Durez P, Malghem J, Toukap AN, Depresseux G, Lauwerys BR, Westhovens R, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis & Rheumatism. 2007;56(12):3919.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Clair EWS, Heijde DMvd, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis and Rheumatism. 2004;50(11):3432.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Emery Pea. Two-Year Clinical and Radiographic Results With Combination Etanercept–Methotrexate Therapy Versus Monotherapy in Early Rheumatoid Arthritis. ARTHRITIS & RHEUMATISM. 2010;62(3):674-82.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: RIGBY WF, G.; GREENWALD, M.; ZAZUETA-MONTIEL, B.; et. al. Effect of Rituximab on Physical Function and Quality of Life in Patients With Rheumatoid Arthritis Previously Untreated With Methotrexate. American College of Rheumatology. 2011;63(5):711-20.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Svensson B, Boonen A, Albertsson K, Heijde Dvd, Keller C, Hafstrom I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis & Rheumatism. 2005;52(11):3360.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Ajeganova S, Svensson B, Hafstrom I. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open. 2014;4(4).
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Annals of the Rheumatic Diseases. 2004;63(7):797.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Braun J. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis & Rheumatism. 2008;58(1):73.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Jordan N, Chaib A, Sangle S, et al. Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients. Arthritis Care Res (Hoboken) 2014; 66: 725-731.
Study design: Other Observational Study
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Mejía-Vilet JM, Márquez-Martínez MA, Cordova-Sanchez BM, et al. Simple risk score for prediction of haemorrhagic complications after a percutaneous renal biopsy. Nephrology (Carlton) 2018; 23: 523-529.
Study design: Other Observational Study
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Tøndel C, Vikse BE, Bostad L, et al. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. Clinical journal of the American Society of Nephrology : CJASN 2012; 7: 1591-1597.
Study design: Other Observational Study
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Yu MC, Lee F, Huang WH, et al. Percutaneous ultrasound-guided renal biopsy in children: The need for renal biopsy in pediatric patients with persistent asymptomatic microscopic hematuria. Biomed J 2014; 37: 391-397.
Study design: Other Observational Study
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Bluhme E, Malenicka S, Fischler B, et al. Comparison of cystatin C, creatinine, and iohexol clearance in pediatric liver transplantation-a retrospective cohort study. Pediatr Transplant 2021; 25: e13993.
Study design: Other Observational Study
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: De Souza V, Hadj-Aissa A, Dolomanova O, et al. Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Hepatology 2013; 59: 1522-1531.
Study design: Other Observational Study
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Inker LA, Levey AS, Tighiouart H, et al. Performance of glomerular filtration rate estimating equations in a community-based sample of Blacks and Whites: the multiethnic study of atherosclerosis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2017; 33: 417-425.
Study design: Other Observational Study
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Liu X, Ma H, Huang H, et al. Is the Chronic Kidney Disease Epidemiology Collaboration creatinine-cystatin C equation useful for glomerular filtration rate estimation in the elderly? Clin Interv Aging 2013; 8: 1387-1391.
Study design: Other Observational Study
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Machado JD, Camargo EG, Boff R, et al. Combined creatinine-cystatin C CKD-EPI equation significantly underestimates measured glomerular filtration rate in people with type 2 diabetes mellitus. Clin Biochem 2018; 53: 43-48.
Study design: Other Observational Study
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Werner K, Pihlsgård M, Elmståhl S, et al. Combining Cystatin C and Creatinine Yields a Reliable Glomerular Filtration Rate Estimation in Older Adults in Contrast to β-Trace Protein and β2-Microglobulin. Nephron 2017; 137: 29-37.
Study design: Other Observational Study
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Björk J, Grubb A, Gudnason V, et al. Comparison of glomerular filtration rate estimating equations derived from creatinine and cystatin C: validation in the Age, Gene/Environment Susceptibility-Reykjavik elderly cohort. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2017; 33: 1380-1388.
Study design: Other Observational Study
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Fan L, Inker LA, Rossert J, et al. Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2014; 29: 1195-1203.
Study design: Other Observational Study
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Medina Arnaudo GI. [Evaluation of equations using cystatin C for estimation of the glomerular filtration rate in healthy adult population of canidates for kidney donors.]. Rev Fac Cien Med Univ Nac Cordoba 2018; 74: 243-250.
Study design: Other Observational Study
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Gunawardhana L, Becker MA, Whelton A, et al. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis research & therapy 2018; 20: 99.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Saag KG, Whelton A, Becker MA, et al. Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis and Rheumatology 2016; 68: 2035-2043.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Tanaka K, Nakayama M, Kanno M, et al. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clinical and experimental nephrology 2015; 19: 1044‐1053.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Wada T, Hosoya T, Honda D, et al. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). Clinical and Experimental Nephrology 2018; 22: 860-870.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long - term follow - up of a randomized clinical trial. Am J Kidney Dis 2015; 65: 543-549.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6 - Month, Double - Blind, Randomized, Placebo - Controlled Trial. Am J Kidney Dis 2015; 66: 945-950.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Kimura K, Hosoya T, Uchida S, et al. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; 72: 798-810.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Wen H, Yongling Z, Shuying Z, et al. Effect of febuxostat on renal function in patients from South China with CKD3 diabetic nephropathy. Jornal Brasileiro de Nefrologia 2020; 42: 393 - 399.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Beddhu S, Filipowicz R, Wang B, et al. A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy. Canadian journal of kidney health and disease 2016; 3: 2054358116675343.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Wolfe R, Wetmore JB, Woods RL, et al. Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney Int 2021; 99: 466-474.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 2010; 56: 956-965.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Goicoechea M, de Vinuesa SG, Quiroga B, et al. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). Cardiovasc Drugs Ther 2018; 32: 255-263.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Hastings RS, Hochman JS, Dzavik V, et al. Effect of late revascularization of a totally occluded coronary artery after myocardial infarction on mortality rates in patients with renal impairment. Am J Cardiol 2012; 110: 954-960.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Charytan DM, Wallentin L, Lagerqvist B, et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clinical journal of the American Society of Nephrology : CJASN 2009; 4: 1032-1043.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Chashkina MI, Andreev DA, Kozlovskaya NL, et al. [Safety performance of rivaroxaban versus warfarin in patients with atrial fibrillation and advanced chro-nic kidney disease]. Kardiologiia 2020; 60: 1322.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387-2394.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics: